Relapse Rates Lower With Ofatumumab in Multiple Sclerosis
Annualized relapse rates lower for ofatumumab versus teriflunomide in two identical phase 3 trials
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.